Goldman Sachs Group Inc Hepion Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $555 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.57 - $1.22 $8,524 - $18,246
-14,956 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$0.93 - $1.29 $18,770 - $26,036
-20,183 Reduced 57.44%
14,956 $19,000
Q4 2021

Feb 14, 2022
BUY
$1.14 - $1.58 $26,885 - $37,262
23,584 Added 204.1%
35,139 $40,000
Q3 2021

Nov 10, 2021
BUY
$1.39 - $2.1 $16,061 - $24,265
11,555 New
11,555 $18,000

About Hepion Pharmaceuticals, Inc.

HEPA Quotes by TradingView
  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $96M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email